News Focus
News Focus
icon url

rkrw

09/20/11 7:13 AM

#126890 RE: DewDiligence #126889

MNTA prospects are terrific if they get a timely generic Copaxone approval. If not, then I would think there are many biotechs with better prospects. There's an opportunity cost if it takes a lot longer than you may expect.